Literature DB >> 29926118

[Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

S M Schellong1, H Riess2, M Spannagl3, H Omran4, M Schwarzbach5, F Langer6, W Gogarten7, P Bramlage8, R M Bauersachs9,10.   

Abstract

Approximately 30% of patients receiving oral anticoagulation using vitamin K antagonists (VKA) require surgery within 2 years. In this context, a clinical decision on the need and the mode of a peri-interventional bridging with heparin is needed. While a few years ago, bridging was almost considered a standard of care, recent study results triggered a discussion on which patients will need bridging at all. Revisiting the currently available recommendations and study results the conclusion can be drawn that the indications for bridging with heparin must nowadays be taken more narrowly and considering the individual patient risk of bleeding and thromboembolism. Bridging with heparin is only needed in patients with a very high risk of thromboembolism. This overview aims to give guidance for a risk-adapted peri-interventional approach to management of patients with a need for long-term anticoagulation using VKA.

Entities:  

Keywords:  Heparin, low molecular weight; International Normalized Ratio; Perioperative care; Risk, hemorrhage; Risk, thromboembolism

Year:  2018        PMID: 29926118     DOI: 10.1007/s00101-018-0463-0

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  20 in total

Review 1.  Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology.

Authors:  Wiebke Gogarten; Erik Vandermeulen; Hugo Van Aken; Sibylle Kozek; Juan V Llau; Charles M Samama
Journal:  Eur J Anaesthesiol       Date:  2010-12       Impact factor: 4.330

2.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Management of antithrombotic therapy in patients undergoing invasive procedures.

Authors:  Todd H Baron; Patrick S Kamath; Robert D McBane
Journal:  N Engl J Med       Date:  2013-05-30       Impact factor: 91.245

Review 4.  Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.

Authors:  A C Spyropoulos; J D Douketis; G Gerotziafas; S Kaatz; T L Ortel; S Schulman
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

5.  Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.

Authors:  Pierre Sié; Charles M Samama; Anne Godier; Nadia Rosencher; Annick Steib; Juan V Llau; Philippe Van der Linden; Gilles Pernod; Thomas Lecompte; Isabelle Gouin-Thibault; Pierre Albaladejo
Journal:  Arch Cardiovasc Dis       Date:  2011-10-29       Impact factor: 2.340

6.  Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Authors:  James D Douketis; Alex C Spyropoulos; Scott Kaatz; Richard C Becker; Joseph A Caprini; Andrew S Dunn; David A Garcia; Alan Jacobson; Amir K Jaffer; David F Kong; Sam Schulman; Alexander G G Turpie; Vic Hasselblad; Thomas L Ortel
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

7.  Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.

Authors:  James D Douketis; Jeff S Healey; Martina Brueckmann; John W Eikelboom; Michael D Ezekowitz; Mandy Fraessdorf; Herbert Noack; Jonas Oldgren; Paul Reilly; Alex C Spyropoulos; Lars Wallentin; Stuart J Connolly
Journal:  Thromb Haemost       Date:  2014-12-04       Impact factor: 5.249

Review 8.  Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.

Authors:  Michael Makris; Joost J van Veen; Rhona Maclean
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

Review 9.  Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates.

Authors:  Deborah Siegal; Jovana Yudin; Scott Kaatz; James D Douketis; Wendy Lim; Alex C Spyropoulos
Journal:  Circulation       Date:  2012-08-21       Impact factor: 29.690

10.  Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Authors:  Benjamin A Steinberg; Eric D Peterson; Sunghee Kim; Laine Thomas; Bernard J Gersh; Gregg C Fonarow; Peter R Kowey; Kenneth W Mahaffey; Matthew W Sherwood; Paul Chang; Jonathan P Piccini; Jack Ansell
Journal:  Circulation       Date:  2014-12-12       Impact factor: 29.690

View more
  1 in total

1.  Perioperative Management of Anticoagulants in Ocular Surgeries.

Authors:  Xu He; Alexander F Chen; Rajinder S Nirwan; Jayanth Sridhar; Ajay E Kuriyan
Journal:  Int Ophthalmol Clin       Date:  2020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.